Enterprise Financial Services Corp Alnylam Pharmaceuticals, Inc. Transaction History

Enterprise Financial Services Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$169.75 - $207.73 $7,978 - $9,763	-47 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$128.63 - $176.89 $1,672 - $2,299	13 Added 38.24%	47 $8,000
Q4 2020 Feb 12, 2021	BUY	$122.97 - $147.0 $737 - $882	6 Added 21.43%	34 $5,000
Q2 2020 Aug 04, 2020	BUY	$104.21 - $156.44 $2,396 - $3,598	23 Added 460.0%	28 $4,000
Q1 2020 May 15, 2020	BUY	$93.12 - $133.99 $465 - $669	5 New	5 $1,000
Q4 2018 Jan 25, 2019	SELL	$62.67 - $88.33 $1,190 - $1,678	-19 Closed	0 $0
Q3 2018 Oct 26, 2018	BUY	$87.52 - $122.67 $1,662 - $2,330	19 New	19 $2,000

644

109M

1.28M

1.21M

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $31.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

Get notified when there are updates to the investment portfolio of Enterprise Financial Services Corp, based on Form 13F filings with the SEC.

Stay updated on Enterprise Financial Services Corp with notifications on news.